Singapoo - Kiingereza - HSA (Health Sciences Authority)

pfizer private limited - crm197 protein; pneumococcal polysaccharide serotype 1 (conjugate); pneumococcal polysaccharide serotype 14 (conjugate); pneumococcal polysaccharide serotype 18c (conjugate); pneumococcal polysaccharide serotype 19a (conjugate); pneumococcal polysaccharide serotype 19f (conjugate); pneumococcal polysaccharide serotype 23f (conjugate); pneumococcal polysaccharide serotype 3 (conjugate); pneumococcal polysaccharide serotype 4 (conjugate); pneumococcal polysaccharide serotype 5 (conjugate); pneumococcal polysaccharide serotype 6a (conjugate); pneumococcal polysaccharide serotype 6b (conjugate); pneumococcal polysaccharide serotype 7f (conjugate); pneumococcal polysaccharide serotype 9v (conjugate) - injection, suspension - 32mcg - crm197 protein 32mcg; pneumococcal polysaccharide serotype 1 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 14 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 18c (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 19a (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 19f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 23f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 3 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 4 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 5 (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 6a (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 6b (conjugate) 4.4mcg; pneumococcal polysaccharide serotype 7f (conjugate) 2.2mcg; pneumococcal polysaccharide serotype 9v (conjugate) 2.2mcg

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vaccines - active immunisation against disease caused by streptococcus pneumoniae serotypes 4, 6b, 9v, 14, 18c, 19f and 23f (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from two months up to five years of age.the use of prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas.

Israeli - Kiingereza - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in adults ≥18 years of age and the elderly

Armenia - Kiingereza - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

wyeth pharmaceuticals - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 4.4mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1

Armenia - Kiingereza - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium n.v. - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

Armenia - Kiingereza - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal pol - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumococcal infections - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. see sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.the use of vaxneuvance should be in accordance with official recommendations.

Kanada - Kiingereza - Health Canada

pfizer canada ulc - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 8; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 10a; pneumococcal polysaccharide serotype 11a; pneumococcal polysaccharide serotype 12f; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 15b; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 33f; corynebacterium diphtheriae crm-197 protein - suspension - 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 4.4mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 2.2mcg; 51mcg - pneumococcal polysaccharide serotype 1 2.2mcg; pneumococcal polysaccharide serotype 3 2.2mcg; pneumococcal polysaccharide serotype 4 2.2mcg; pneumococcal polysaccharide serotype 5 2.2mcg; pneumococcal polysaccharide serotype 6a 2.2mcg; pneumococcal polysaccharide serotype 6b 4.4mcg; pneumococcal polysaccharide serotype 7f 2.2mcg; pneumococcal polysaccharide serotype 8 2.2mcg; pneumococcal polysaccharide serotype 9v 2.2mcg; pneumococcal polysaccharide serotype 10a 2.2mcg; pneumococcal polysaccharide serotype 11a 2.2mcg; pneumococcal polysaccharide serotype 12f 2.2mcg; pneumococcal polysaccharide serotype 14 2.2mcg; pneumococcal polysaccharide serotype 15b 2.2mcg; pneumococcal polysaccharide serotype 18c 2.2mcg; pneumococcal polysaccharide serotype 19a 2.2mcg; pneumococcal polysaccharide serotype 19f 2.2mcg; pneumococcal polysaccharide serotype 22f 2.2mcg; pneumococcal polysaccharide serotype 23f 2.2mcg; pneumococcal polysaccharide serotype 33f 2.2mcg; corynebacterium diphtheriae crm-197 protein 51mcg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

pfizer private limited - crm197 protein; pneumococcal polysaccharide serotype 1 (conjugate); pneumococcal polysaccharide serotype 10a (conjugate); pneumococcal polysaccharide serotype 11a (conjugate); pneumococcal polysaccharide serotype 12f (conjugate); pneumococcal polysaccharide serotype 14 (conjugate); pneumococcal polysaccharide serotype 15b (conjugate); pneumococcal polysaccharide serotype 18c (conjugate); pneumococcal polysaccharide serotype 19a (conjugate); pneumococcal polysaccharide serotype 19f (conjugate); pneumococcal polysaccharide serotype 22f (conjugate); pneumococcal polysaccharide serotype 23f (conjugate); pneumococcal polysaccharide serotype 3 (conjugate); pneumococcal polysaccharide serotype 33f (conjugate); pneumococcal polysaccharide serotype 4 (conjugate); pneumococcal polysaccharide serotype 5 (conjugate); pneumococcal polysaccharide serotype 6a (conjugate); pneumococcal polysaccharide serotype 6b (conjugate); pneumococcal polysaccharide serotype 7f (conjugate); pneumococcal polysaccharide serotype 8 (conjugate); pneumococcal polysaccharide serotype 9v (conjugate) - injection, suspension - crm197 protein approx. 51 μg/0.5ml; pneumococcal polysaccharide serotype 1 (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 10a (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 11a (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 12f (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 14 (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 15b (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 18c (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 19a (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 19f (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 22f (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 23f (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 3 (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 33f (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 4 (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 5 (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 6a (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 6b (conjugate) 4.4 μg/0.5ml; pneumococcal polysaccharide serotype 7f (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 8 (conjugate) 2.2 μg/0.5ml; pneumococcal polysaccharide serotype 9v (conjugate) 2.2 μg/0.5ml

Armenia - Kiingereza - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer manufacturing belgium nv - pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f) - suspension for injection - 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 4.4mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose+ 2.2mcg/dose